Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

The molecular basis of T cell allorecognition in Graft-versus-Host-Disease and Graft-versus-Leukemia

Award Number: F31AI197535
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 09/01/2026
PERIOD OF PERFORMANCE END DATE: 08/31/2029

Group Awards By:

View Award Description

The molecular basis of T cell allorecognition in Graft-versus-Host-Disease and Graft-versus-Leukemia - PROJECT SUMMARY T cells play an integral role in defending hosts from pathogens and cancer through T cell receptor (TCR) recognition of peptides displayed on Major Histocompatibility Complexes (MHC). T cells typically recognize peptides presented on self-MHC, which provides important protection against infection and cancer. A portion of the T cell repertoire also has the ability to recognize peptides displayed on non-self MHC, or allogeneic MHC (allo-MHC). This phenomenon, known as alloreactivity, is encountered during organ transplantation between genetically distinct individuals. Alloreactivity poses substantial challenges for successful organ transplantation. After allogeneic hematopoietic stem cell transplantation (allo-HSCT), transplanted alloreactive donor T cells can attack healthy host tissues, resulting in fatal Graft-versus-Host-Disease. However, alloreactivity after allo-HSCT can also be beneficial — in an effect known as Graft-versus-Leukemia (GvL), alloreactive donor T cells eliminate residual cancer cells, greatly reducing the risk of disease relapse. Efforts have been made to strengthen the GvL response, but GvL and GvHD often co-occur, resulting in accompanying toxicity against healthy tissues. Despite the well-established phenomenon of GvHD and GvL, our understanding of the interactions that drive these two responses, and how linked they are, remains limited. The overall objective of this proposal is to determine the molecular mechanisms underlying T cell allorecognition in GvHD and GvL through a repertoire-scale examination. I will utilize a single MHC-mismatched bone marrow transplant and tumor model to study alloreactive TCRs against a single MHC in GvHD and GvL, which will allow for comprehensive deconstruction of the underlying mechanisms. Aim 1 will focus on characterizing alloreactive GvHD and GvL T cell repertoires. Experiments will determine the TCR clones involved in GvHD and GvL, their tissue-specificities, and the extent to which they overlap. Aim 2 will then focus on identifying the antigen targets and characterizing the cross- reactivity patterns of these TCRs. We will utilize a library-on-library lentivirus-based screening method developed by our laboratory to map TCRs to their cognate antigens on a repertoire scale, which will reveal the antigens recognized during GvHD and GvL, whether there are shared antigens targeted by these two responses, and the extent of cross-reactivity of individual TCRs. Collectively, these findings will advance our understanding of the molecular interactions driving GvHD and GvL and the extent to which they overlap, providing critical insight for therapeutic efforts to selectively improve GvL responses while limiting GvHD. The proposed research and training plan will equip the candidate with advanced technical skills and knowledge in immunology and engineering, as well as training in rigorous experimental design and interpretation, which together will help the candidate develop into an independent scientist prepared to conduct and lead impactful immune engineering research.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $50,114 )
2026	2026	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	77 MASSACHUSETTS AVE	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Allergy and Infectious Diseases Research	001	1	5/11/2026	NEW	$0
2026	2026	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	77 MASSACHUSETTS AVE	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Allergy and Infectious Diseases Research	000	1	5/11/2026	NEW	$50,114
														Subtotal = $50,114

Grand Total All Awards = $50,114

Top

All Categories

About

Search

Reports

Data Submission

Award Information

The molecular basis of T cell allorecognition in Graft-versus-Host-Disease and Graft-versus-Leukemia

Award Number: F31AI197535

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 09/01/2026

PERIOD OF PERFORMANCE END DATE: 08/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer